Skip to main content

Currently, there are no approved on-hand rescue treatments for acute anxiety episodes or panic attacks

There are more than 40 million people in the United States with anxiety disorders. Acute episodes can occur in all major types—generalized anxiety, obsessive-compulsive disorder, post-traumatic stress disorder, social phobia, and panic disorder. Up to 75% of patients with panic disorder will experience an acute panic attack—even though they may be taking daily chronic therapy, these attacks can be terrifying and impact approximately 2.4 million adults annually.
Presently, there are no FDA-approved products indicated for the treatment of acute anxiety episodes. Patients can take oral alprazolam or lorazepam administered at acute anxiety episode onset, but these products can take 30 minutes or more to become clinically effective.

About NRL-2

  • NRL-2 is being developed as an acute rescue therapy
 for patients with anxiety who suffer from debilitating acute anxiety episodes, such as panic attacks.*


  • NRL-2 is a proprietary formulation of intranasal lorazepam utilizing Neurelis' technology platform.


  • NRL-2 is in the initial (formulation) stage of development and presents a worldwide commercial opportunity for Neurelis.

*NRL-2 is a drug candidate being developed for children and adults who require intermittent use of diazepam for acute anxiety episodes and has not been approved by FDA for any indication.